[1]
Ferroni, P.; Silvia, R.; Vincenzo, F.; Vittore, C.; Livia, T.; Francesca, L.F.; Maria, G.V.; Matteo, V.; Fiorella, G.; Mario, R. Clinical significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in venous thromboembolism (VTE) risk prediction in ambulatory cancer patients treated with chemotherapy. Int. J. Cancer, 2015, 136(5), 1234-1240.
[2]
Ferroni, P.; Silvia, R.; Oreste, B.; Raffaele, P.; Fiorella, G.; Mario, R. Type 2 diabetes and breast cancer: The interplay between impaired glucose metabolism and oxidant stress. Oxid. Med. Cell. Longev., 2015, 183928.
[3]
Riondino, S.; Ferroni, P.; Spila, A.; Alessandroni, J.; D’Alessandro, R.; Formica, V.; Della-Morte, D.; Palmirotta, R.; Nanni, U.; Roselli, M.; Guadagni, F. Ensuring sample quality for biomarker discovery studies – use of ICT tools to trace biosample life-cycle. Cancer Genomics Proteomics, 12(6) 2015 291-299
[4]
Ferroni, P.; Palmirotta, R.; Riondino, S.; De Marchis, M.L.; Nardecchia, A.; Formica, V.; Guadagni, F.; Roselli, M. VEGFA gene promoter polymorphisms and risk of venous thromboembolism in chemotherapy treated cancer patients. Thromb. Haemost., 2016, 115(1), 143-151.
[5]
Ferroni, P.; Mario, R.; Riondino, S.; Cavaliere, F.; Guadagni, F. Insulin resistance and risk of venous thromboembolism in breast cancer. Endocr. Relat. Cancer, 2016, 23(6), L25-L28.
[6]
Ferroni, P. Riondino,S.; Laudisi, A.; Portarena, I.; Formica, V.; Alessandroni, J.; Alessandro, R.D.; Orlandi, A.; Costarelli, L.; Cavaliere, F.; Guadagni, F.; Roselli, M. Pre-treatment insulin levels as a prognostic factor for breast cancer progression. Oncologist, 2016, 21(9), 1041-1049.
[7]
Roselli, M.; Formica, V.; Cereda, V.; Jochems, C.; Richards, J.; Grenga, I.; Orlandi, A.; Ferroni, P.; Guadagni, F.; Schlom, J. The association of clinical outcome and peripheral T-cell subsets in metastatic colorectal cancer patients receiving first-line FOLFIRI plus bevacizumab therapy. OncoImmunology, 2016, 5(7), e1188243.
[8]
Khanna, S.; Thomas, A.; Abate-Daga, D.; Zhang, J.; Morrow, B.; Steinberg, S.M.; Orlandi, A.; Ferroni, P.; Schlom, J.; Guadagni, F.; Hassan, R. PD-L1 is highly expressed in malignant mesothelioma and PD-1+ lymphocytes within malignant effusions induce tumor PD-L1 expression. J. Thorac. Oncol., 2016, 11(11), 1993-2005.
[9]
Hamilton, D.D.; Roselli, M.; Ferroni, P.; Costarelli, L.; Cavaliere, F.; Taffuri, M.; Palena, C.; Guadagni, F. Brachyury, a vaccine target, is overexpressed in triple negative breast cancer. Endocr. Relat. Cancer, 2016, 23(10), 783-796.
[10]
Ferroni, P.; Formica, V.; Della-Morte, D.; Lucchetti, J.; Spila, A.; Alessandro, R.D.; Riondino, S.; Guadagni, F.; Roselli, M. Prognostic value of glycated hemoglobin in colorectal cancer. World J. Gastroenterol., 2016, 22(45), 9984-9993.
[11]
Ferroni, P.; Santilli, F.; Cavaliere, F.; Simeone, P.; Costarelli, L.; Liani, R.; Tripaldi, R.; Riondino, S.; Roselli, M.; Davi, G.; Guadagni, F. Oxidant stress as a major determinant of platelet activation in invasive breast cancer. Int. J. Cancer, 2017, 140(3), 696-704.
[12]
Ferroni, P.; Zanzotto, F.M.; Scarpato, N.; Riondino, S.; Nanni, U.; Roselli, M.; Guadagni, F. Risk assessment for venous thromboembolism in chemotherapy treated ambulatory cancer patients: A precision medicine approach. Med. Decis. Making, 2017, 37(2), 234-242.
[13]
Ferroni, P. et al.Increased thrombophilic predisposition in premenopausal females with chronic migraine. Neurology, 2017, 89(14), 1525-1527.
Related Journals
Current Pharmaceutical Design
Current Topics in Medicinal Chemistry
Current Respiratory Medicine Reviews
Infectious Disorders - Drug Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets
Anti-Infective Agents
Coronaviruses
Recent Advances in Inflammation & Allergy Drug Discovery
Current Probiotics
Article Metrics
21
3
1
1